Peripheral blood mononuclear cells were isolated from a healthy human subject and was screened by ELISA against a panel of recombinant soluble HA proteins
≥ 5.0 mg/ml
≤ 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Standard Overnight on Blue Ice.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Flu-5J8 activity is directed against a conserved H1 epitope adjacent to the receptor binding site domain on the HA globular head. Furthermore, clone Flu-5J8 binds HA using receptor mimicry3. By inserting its HCDR3 into the HA receptor binding site (RBS), Flu-5J8 closely mimics the natural sialoglycan receptor and blocks viral-host interactions. Flu-5J8 contacts the Sb and Ca2 antigenic sites and binds to conserved residues in the RBS (130 loop, 190 helix, and 220 loop) as well as outside the RBS at the 140 loop. Furthermore, EM reconstructions show that Flu-5J8 occupies all three potential binding sites at the HA apex at and around the RBS. Mutations located between the receptor-binding pocket and the Ca2 antigenic site at residues 133A, 137, or 222 eliminate binding.
In a lethal challenge in mice, Flu-5J8 protected all animals at the high and medium doses given and reduced lung virus titers relative to the control2.
HA is on the viral surface.
Hemagglutinin (HA) is a glycoprotein on the Influenza A (IAV) viral surface1. HA consists of two domains: an antigenically variable head and a more conserved stem. There are 18 HA subtypes. Neutralizing antibodies targeting the head domain are typically restricted to within subtype, while antibodies targeting the stem offer broader protection. In contrast, Flu-5J8 targets the HA globular head and offers broad protection2. Flu-5J8 inhibits all 1918 to 1977 H1N1 strains tested plus the pandemic 2009 strain but not the seasonal H1N1 strains from 1999 or 2007.
References & Citations
1. Bangaru S, Lang S, Schotsaert M, et al. Cell. 177(5):1136-1152.e18. 2019.
2. Krause JC, Tsibane T, Tumpey TM, et al. J Virol.85(20):10905-10908. 2011.
3. Hong M, Lee PS, Hoffman RM, et al. J Virol. 87(22):12471-12480. 2013.
4. Lee J, Boutz DR, Chromikova V, et al. Nat Med. 22(12):1456-1464. 2016.
5. Gilchuk P, Bombardi RG, Erasmus JH, et al. Nat Biomed Eng. 4(11):1030-1043. 2020.
6. Zost SJ, Dong J, Gilchuk IM, et al. J Clin Invest. 2;131(15):e146791. 2021.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.